Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CareRxFRA:29C1 66 EBIT per Share is €0.11 as of Jun. 2026. GuruFocus rates FRA:29C1 with a GF Score™ of 66/100 and a GF Value™ of €1.37. The stock has 3 warning signs investors should review. Among 522 Healthcare Providers & Services companies, CareRx ranks worse than 61.88% on this metric.
CareRx's EBIT per Share for the
three
months ended in Jun. 2026 was €0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €0.11.
During the past 12 months, the average EBIT per Share Growth Rate of CareRx was 46.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 4.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for CareRx's EBIT per Share or its related term are showing as below:
FRA:29C1'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -40.5 Med: 0.5 Max: 59.8
Current: 4.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of CareRx was 59.80% per year. The lowest was -40.50% per year. And the median was 0.50% per year.
FRA:29C1's 3-Year EBIT Growth Rate is ranked worse than 61.88% of 522
companies
in the Healthcare Providers & Services industry
Industry Median: 11.75
vs FRA:29C1: 4.80
CareRx's EBIT for the
three
months ended in Jun. 2026 was €1.3 Mil.
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
CareRx EBIT per Share Related Terms
CareRx EBIT per Share Historical Data
* Premium members only.
The historical data trend for CareRx's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.11
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CareRx (FRA:29C1) has a EBIT per Share of €0.11 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CareRx and its competitors. According to the industry distribution chart, CareRx ranks #323 out of 522 companies in the Healthcare Providers & Services industry, placing it in the top 61.9%.
Is CareRx's EBIT per Share too high?
CareRx's current EBIT per Share is €0.11. Based on the distribution chart, CareRx ranks #323 out of 522 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, CareRx has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does CareRx's EBIT per Share compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, CareRx ranks #323 out of 522 companies for EBIT per Share. This places CareRx in the lower half of its industry. The industry median EBIT per Share is 11.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.75, based on 522 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CareRx and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CareRx's current EBIT per Share is €0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareRx stock overvalued right now?
CareRx (FRA:29C1) has a current EBIT per Share of €0.11. The stock's GF Value™ is €1.37, compared to a current price of €2.04 — trading 48.9% above its estimated fair value. The current EBIT per Share is €0.11. CareRx's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For CareRx (FRA:29C1), the current EBIT per Share is €0.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CareRx (FRA:29C1) Overvalued in 2026?
Based on GuruFocus' analysis, CareRx stock appears to be overvalued.
The current stock price of €2.04 is trading 48.9% above its estimated GF Value™ of €1.37.
Key valuation signals for FRA:29C1:
EBIT per Share: €0.11
GF Value™: €1.37 vs. price of €2.04 (48.9% above fair value)
No single metric tells the full story. See the FRA:29C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CareRx Corp is a provider of specialty pharmacy services to seniors. The company is a national organization with a large network of pharmacy fulfilment centers strategically located across the country. This allows it to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. It takes an active role in working with its home operator partners to promote resident health, staff education and medication system quality and efficiency. The Company has one reportable segment which consists of the Company-owned and operated institutional pharmacy business. Geographically it derives revenue from the sales of goods and capitated service fees in Ontario and Western Canada.
66GF Score
Get the complete analysis for FRA:29C1
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:29C1 has been successfully added to your 
